Avalo Therapeutics (AVTX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases.

• Lead asset AVTX-009 is in Phase 2 clinical trial for hidradenitis suppurativa (HS), with topline data expected in Q2 2026.

• Strategy includes advancing pipeline to regulatory approval, expanding indications, acquiring or in-licensing complementary compounds, and out-licensing rights opportunistically.

• Principal executive offices are in Wayne, Pennsylvania.

Financial performance and metrics

• Classified as a "smaller reporting company" under SEC rules, with market value and revenue thresholds below $250 million and $100 million, respectively.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for general corporate purposes, including clinical trials, R&D, and administrative expenses.

• Proceeds may be temporarily invested in investment grade, interest-bearing instruments or U.S. government securities.